Hydrogel Drug Delivery System Using Self-Cleaving Covalent Linkers for Once-a-Week Administration of Exenatide

Bioconjugate Chemistry

Volumn 27, Issue 5, 2016, Pages 1210-1215

  Schneider, Eric L ^a   Henise, Jeff ^a   Reid, Ralph ^a   Ashley, Gary W ^a   Santi, Daniel V ^a  

^a ProLynx   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTROLLED DRUG DELIVERY; HYDROGELS; PEPTIDES; PHARMACOKINETICS; RATS; TARGETED DRUG DELIVERY;

CLEAVAGE RATES; COVALENT LINKERS; DRUG RELEASE; DRUG-DELIVERY SYSTEMS; FLOW FOCUSING; HALF LIVES; HYDROGEL MICROSPHERES; IN-VITRO; IN-VIVO; MICROFLUIDICS DEVICES;

MICROSPHERES;

EXENDIN 4; MICROSPHERE; DRUG CARRIER; HYDROGEL; MACROGOL DERIVATIVE; PEPTIDE; VENOM;

ACYLATION; ANIMAL EXPERIMENT; ARTICLE; BIODEGRADATION; COVALENT BOND; DEGRADATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; ELIMINATION RATE CONSTANT; GELATION; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MICROFLUIDICS; MINIMUM PLASMA CONCENTRATION; NONHUMAN; POLYMERIZATION; RAT; SLOW DRUG RELEASE; STEADY STATE; ANIMAL; CHEMISTRY; CONFORMATION; DRUG ADMINISTRATION; HUMAN; MOLECULAR MODEL;

ANIMALS; DRUG ADMINISTRATION SCHEDULE; DRUG CARRIERS; HUMANS; HYDROGELS; MICROSPHERES; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PEPTIDES; POLYETHYLENE GLYCOLS; RATS; VENOMS;

EID: 84971238372     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/acs.bioconjchem.5b00690     Document Type: Article

References (31)

1. McDonald, A. I. and Isaacson, J. (2012) Bydureon Survey, LifeSci Advisors; http://www.lifesciadvisors.com/clientinfo/marketresearch/marketresearch-Bydureon%20Survey-2-19-2012-clientinfo.pdf.
2. Madsbad, S., Kielgast, U., Asmar, M., Deacon, C. F., Torekov, S. S., and Holst, J. J. (2011) An overview of once-weekly glucagon-like peptide-1 receptor agonists - available efficacy and safety data and perspectives for the future Diabetes, Obes. Metab. 13, 394-407 10.1111/j.1463-1326.2011.01357.x
3. Tibble, C. A., Cavaiola, T. S., and Henry, R. R. (2013) Longer Acting GLP-1 Receptor Agonists and the Potential for Improved Cardiovascular Outcomes Expert Rev. Endocrinol. Metab. 8, 247-259 10.1586/eem.13.20
4. Henry, R. R., Rosenstock, J., Logan, D., Alessi, T., Luskey, K., and Baron, M. A. (2014) Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes J. Diabetes Complications 28, 393-8 10.1016/j.jdiacomp.2013.12.009
5. Santi, D. V., Schneider, E. L., Reid, R., Robinson, L., and Ashley, G. W. (2012) Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates Proc. Natl. Acad. Sci. U. S. A. 109, 6211-6 10.1073/pnas.1117147109
6. Ashley, G. W., Henise, J., Reid, R., and Santi, D. V. (2013) Hydrogel drug delivery system with predictable and tunable drug release and degradation rates Proc. Natl. Acad. Sci. U. S. A. 110, 2318-23 10.1073/pnas.1215498110
7. Sakai, T., Matsunaga, T., Yamamoto, Y., Ito, C., Yoshida, R., Suzuki, S., Sasaki, N., Shibayama, M., and Chung, U.-i. (2008) Design and Fabrication of a High-Strength Hydrogel with Ideally Homogeneous Network Structure from Tetrahedron-like Macromonomers Macromolecules 41, 5379-5384 10.1021/ma800476x
8. Henise, J., Hearn, B. R., Ashley, G. W., and Santi, D. V. (2015) Biodegradable tetra-PEG hydrogels as carriers for a releasable drug delivery system Bioconjugate Chem. 26, 270-8 10.1021/bc5005476
9. Holtze, C., Rowat, A. C., Agresti, J. J., Hutchison, J. B., Angile, F. E., Schmitz, C. H., Koster, S., Duan, H., Humphry, K. J., and Scanga, R. A. et al. 2008, Biocompatible surfactants for water-in-fluorocarbon emulsions Lab Chip 8, 1632-9 10.1039/b806706f
10. Steinhilber, D., Rossow, T., Wedepohl, S., Paulus, F., Seiffert, S., and Haag, R. (2013) A microgel construction kit for bioorthogonal encapsulation and pH-controlled release of living cells Angew. Chem., Int. Ed. 52, 13538-43 10.1002/anie.201308005
11. Lasch, P., Nattermann, H., Erhard, M., Stammler, M., Grunow, R., Bannert, N., Appel, B., and Naumann, D. (2008) MALDI-TOF mass spectrometry compatible inactivation method for highly pathogenic microbial cells and spores Anal. Chem. 80, 2026-34 10.1021/ac701822j
12. Baumhover, N. J., Martin, M. E., Parameswarappa, S. G., Kloepping, K. C., O'Dorisio, M. S., Pigge, F. C., and Schultz, M. K. (2011) Improved synthesis and biological evaluation of chelator-modified alpha-MSH analogs prepared by copper-free click chemistry Bioorg. Med. Chem. Lett. 21, 5757-61 10.1016/j.bmcl.2011.08.017
13. Westman, A. E. R. and DeLury, D. B. (1956) The differential equations of consecutive reactions Can. J. Chem. 34, 1134-1138 10.1139/v56-147
14. Parkes, D., Jodka, C., Smith, P., Sonali Nayak, S., Rinehart, L., Gingerich, R., K, C., and Young, A. (2001) Pharmacokinetic Actions of Exendin-4 in the Rat: Comparison With Glucagon-Like Peptide-1 Drug Dev. Res. 53, 260-267 10.1002/ddr.1195
15. Nelder, J. A. and Mead, R. (1965) A simplex method for function minimization Computer Journal 7, 308-313 10.1093/comjnl/7.4.308
16. Gao, W. and Jusko, W. J. (2011) Pharmacokinetic and pharmacodynamic modeling of exendin-4 in type 2 diabetic Goto-Kakizaki rats J. Pharmacol. Exp. Ther. 336, 881-90 10.1124/jpet.110.175752
17. Sakore, S. and Chakraborty, B. (2011) In Vitro-In Vivo Correlation (IVIVC): A Strategic Tool in Drug Development J. Bioequiv Availab S3, 1-12
18. FDA Guidancefor Industry Extended Release Oral Dosage Forms: Development, E.,and Application of In Vitro/In Vivo Correlations. ((1997).
19. Wagner, J. G. and Nelson, E. (1963) Per cent absorbed time plots derived from blood level and/or urinary excretion data J. Pharm. Sci. 52, 610 10.1002/jps.2600520629
20. Santi, D. V., Schneider, E. L., and Ashley, G. W. (2014) Macromolecular prodrug that provides the irinotecan (CPT-11) active-metabolite SN-38 with ultralong half-life, low C(max), and low glucuronide formation J. Med. Chem. 57, 2303-14 10.1021/jm401644v
21. Hauck, W. W., Tozer, T. N., Anderson, S., and Bois, F. Y. (1998) Considerations in the attainment of steady state: aggregate vs. individual assessment Pharm. Res. 15, 1796-8 10.1023/A:1011933401522
22. Byetta, P. i. Prescribing information.
23. Drucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., and Porter, L. (2008) Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study Lancet 372, 1240-50 10.1016/S0140-6736(08)61206-4
24. Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., and Taylor, K. (2007) Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes Diabetes Care 30, 1487-93 10.2337/dc06-2375
25. Finan, B., Ma, T., Ottaway, N., Muller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., and Raver, C. et al. 2013, Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans Sci. Transl. Med. 5, 209ra151 10.1126/scitranslmed.3007218
26. Li, X., Zhao, Z., Li, L., Zhou, T., and Lu, W. (2015) Pharmacokinetics, in vitro and in vivo correlation, and efficacy of exenatide microspheres in diabetic rats Drug Delivery 22, 86-93 10.3109/10717544.2013.871760
27. European Medicines Agency; Byetta: EPAR-Scientific Discussion 12/14/2006; http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human-med-000682.jsp&mid=WC0b01ac058001d124.
28. Zaccardi, F., Htike, Z. Z., Webb, D. R., Khunti, K., and Davies, M. J. (2016) Benefits and Harms of Once-Weekly Glucagon-like Peptide-1 Receptor Agonist Treatments: A Systematic Review and Network Meta-analysis Ann. Intern. Med. 164, 1-12 10.7326/M15-1432
29. Fineman, M., Flanagan, S., Taylor, K., Aisporna, M., Shen, L. Z., Mace, K. F., Walsh, B., Diamant, M., Cirincione, B., and Kothare, P. et al. 2011, Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing Clin. Pharmacokinet. 50, 65-74 10.2165/11585880-000000000-00000
30. Houchin, M. L. and Topp, E. M. (2008) Chemical degradation of peptides and proteins in PLGA: a review of reactions and mechanisms J. Pharm. Sci. 97, 2395-404 10.1002/jps.21176
31. Day, J. W., Ottaway, N., Patterson, J. T., Gelfanov, V., Smiley, D., Gidda, J., Findeisen, H., Bruemmer, D., Drucker, D. J., and Chaudhary, N. et al. 2009, A new glucagon and GLP-1 co-agonist eliminates obesity in rodents Nat. Chem. Biol. 5, 749-57 10.1038/nchembio.209